Major limitations of radiological evaluation of ovarian cancer arise from the inability to consistently detect small lesions. Here, we combine the anatomic imaging capabilities of MRI with the highly sensitive molecular imaging capabilities of PET in an orthotopic syngeneic model of ovarian cancer. [124I]iodo-DPA-713, a macrophage-specific imaging agent, is used to detect and stage ovarian cancer. Specific uptake of the radiotracer was observed within and proximal to the primary tumor at early stages, and in the peritoneal ascitic fluid and within metastases at later stage. These studies will provide insights into ovarian cancer progression that will complement emerging host-directed therapeutics.